-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2642 Predictors and Timing of Venous Thromboembolism in Lymphoma

Program: Oral and Poster Abstracts
Session: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Hodgkin lymphoma, epidemiology, Lymphomas, non-Hodgkin lymphoma, Clinical Research, health outcomes research, thromboembolism, Diseases, Lymphoid Malignancies, Study Population, Human
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Asaad Trabolsi, MD1, Thomas Plate IV, MD1, Rachel S. Kronenfeld, MD2, Leticia E. Campoverde, MD3, Dan Morgenstern Kaplan, MD, MSc4*, Alyssa Mercadel, MD5*, Michael Caballero, PhD6*, Wei Zhao7*, Izidore S. Lossos, MD8, Craig H. Moskowitz, MD9 and Gerald A. Soff, MD10

1Sylvester Comprehensive Cancer Center, University of Miami/ Jackson Memorial Hospital, Miami, FL
2Division of Pediatric Hematology/Oncology, University of Miami/Jackson Memorial Hospital, Miami, FL
3Internal Medicine Residency program, Department of Medicine, University of Miami/ Jackson Memorial Hospital, Miami, FL
4Internal Medicine Residency program, division of internal medicine, Department of Medicine, University of Miami/ Jackson Memorial Hospital, Miami
5Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Miami Leonard M. Miller School of Medicine, Miami
6Data Science and Engineering, UHealth Information Technology, University of Miami, Miami, FL
7Biostatistics and Bioinformatics Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
8Sylvester Comprehensive Cancer Center, Division of Hematology, University of Miami School of Medicine, Miami, FL
9Sylvester Comprehensive Cancer Center, University of Miami, Coral Gables, FL
10Sylvester Comprehensive Cancer Center, University of Miami Miller School of medicine, Miami, FL


Cancer associated thrombosis (CAT) is common in lymphoma, but the risk is not well characterized. While prophylactic anticoagulation is recommended in certain solid tumors, routine prophylaxis is not practiced in hematologic malignancies. The Kohrana CAT risk score considers lymphoma a single entity. We aimed to identify the incidence rate of venous thromboembolism (VTE) and risk factors in lymphoma patients at our institution.


Patients diagnosed with lymphoma between 2018 and 2022 were identified through our institution’s tumor registry. Using automated text search from our electronic medical record (EPIC®) combined with natural language processing review, VTE events were identified from 90 days before and up to one year(y) after initiation of chemotherapy initiation, or diagnosis date if no chemotherapy was administered. VTE events included lower extremity deep vein thrombosis (DVT) or pulmonary embolism (PE). Events were reviewed and adjudicated manually by us. We report time to event analysis and survival analysis using Kaplan-Meier curve. The study was censored at one year. Univariate and multivariate analyses were performed using COX-regression model. We evaluated the effect of indolent versus aggressive lymphoma, stage, age, sex, race, ethnicity, white blood cell count, hemoglobin, and platelet count.


We identified 879 patients(pts) with lymphoma; of those, 378 pts had indolent lymphoma (I-Lym) and 501 pts had aggressive lymphoma (A-Lym). Median age was 61y. 464 pts (52.8%) were above 60 y, 477 pts (54.3%) were males, and 325 pts (37.0%) were Hispanic. Race was distributed as follows: 89.5% white, 9.1% Black, and 1.4% other. 56.9% had advanced stage lymphoma. VTE occurred in 4.9% (n=43) of the overall population within 12 months. The incidence was higher in A-Lym (7.2%, n=36) compared with I-Lym (1.9%, n=7), p<0.001. For both A-Lym and I-Lym, 32.6% of the VTE events occurred prior to diagnosis or initiation of chemotherapy. Among patients who developed thrombosis after the chemotherapy start date, the median time to thrombosis was 39 days.

In a univariate analysis (Table 1) for thrombosis-free survival, age>60, receiving chemotherapy and A-Lym, were all associated with higher risk of thrombosis (p<0.05). In the multivariate analysis, only, age>60, and A-Lym remained significant in predicting thrombosis (HR: 3.48, 95%CI: 1.41, 8.61, p=0.007). Hemoglobin <10, platelet count >350, white blood cell count >11, advanced stage, and chemotherapy administration were not significant risks of thrombosis.

In multivariate analysis for overall survival (Table 2), development of VTE was associated with increased risk of mortality (HR: 2.59, 95%CI: 1.38, 4.87, p=0.003). This relationship of VTE and mortality was observed independently in both I-Lym and A-Lym. As expected, A-Lym, age>60, male sex, and advanced stage all predicted worse survival in our lymphoma population (p<0.05 for all). Of note, hemoglobin <10 and white blood cell count >11, did not predict VTE in lymphoma but did predict poor OS.


Lymphoma is associated with a clinically relevant rate of CAT, but incidence is significantly higher in A-Lym compared with I-Lym with a third of events occurring prior to chemotherapy. The hematologic parameters of the Khorana Score (WBC, Hgb, platelet count) did not correlate with incidence of CAT in lymphoma, neither did chemotherapy. Development of CAT during therapy, in multivariate analysis for both A-Lym and I-Lym, was associated with a marked reduction in OS. These points suggest that the thrombotic risk is an inherent property of lymphoma biology in at least some cases, leading to an increased risk of CAT as well as reduced OS. We do not propose that CAT-related mortality is driving the reduced OS, but more likely a marker of poorer prognosis.


This was a single center/ single dataset and these findings should be considered a derivation cohort, and should be verified with independent additional datasets. If our findings are verified, prospective studies to assess benefit of prophylactic anticoagulation in aggressive lymphoma may be warranted.

Disclosures: Trabolsi: Johnson & Johnson: Current equity holder in publicly-traded company. Kronenfeld: Bayer Healthcare Pharmaceuticals: Research Funding. Caballero: Microsoft Corp: Current equity holder in publicly-traded company; Organon & Co: Current equity holder in publicly-traded company; Exact Sciences Corp: Current equity holder in publicly-traded company; Merck And Co Inc: Current equity holder in publicly-traded company. Lossos: LRF: Membership on an entity's Board of Directors or advisory committees; Adaptive: Honoraria; NCI: Research Funding; NCI: Research Funding; University of Miami: Current Employment; BeiGene: Consultancy. Soff: Anthos Therapeutics: Research Funding; Sanofi: Consultancy.

*signifies non-member of ASH